DE69233468D1 - Prüfung und modell für alzheimers-krankheit - Google Patents

Prüfung und modell für alzheimers-krankheit

Info

Publication number: DE69233468D1
Authority: DE; Germany
Prior art keywords: amino acid; model; test; disease; alzheimer
Prior art date: 1991-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69233468T

Other languages

English (en)

Other versions

DE69233468T2 (de

DE69233468T3 (de

Inventor

John Anthony Hardy

Marie-Christin Chartier-Harlin

Alison Mary Goate

Michael John Owen

Michael John Mullan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Elan Pharmaceuticals LLC

Original Assignee

Elan Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-21

Filing date

1992-01-21

Publication date

2005-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233468(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-01-21 Priority claimed from GB919101307A external-priority patent/GB9101307D0/en

1991-08-28 Priority claimed from GB919118445A external-priority patent/GB9118445D0/en

1992-01-21 Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC

2005-02-17 Publication of DE69233468D1 publication Critical patent/DE69233468D1/de

2005-12-22 Publication of DE69233468T2 publication Critical patent/DE69233468T2/de

2011-05-05 Application granted granted Critical

2011-05-05 Publication of DE69233468T3 publication Critical patent/DE69233468T3/de

2012-01-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

DE69233468T 1991-01-21 1992-01-21 Prüfung und modell für alzheimers-krankheit Expired - Lifetime DE69233468T3 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB919101307A GB9101307D0 (en)	1991-01-21	1991-01-21	Test for alzheimers disease
GB9101307		1991-01-21
GB919118445A GB9118445D0 (en)	1991-08-28	1991-08-28	Test for alzheimer's disease
GB9118445		1991-08-28
PCT/GB1992/000123 WO1992013069A1 (en)	1991-01-21	1992-01-21	Test and model for alzheimer's disease

Publications (3)

Publication Number	Publication Date
DE69233468D1 true DE69233468D1 (de)	2005-02-17
DE69233468T2 DE69233468T2 (de)	2005-12-22
DE69233468T3 DE69233468T3 (de)	2011-05-05

Family

ID=26298303

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE0971033T Pending DE971033T1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE0971033T Pending DE971033T1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Country Status (10)

Country	Link
US (3)	US5877015A (de)
EP (2)	EP0568575B2 (de)
JP (3)	JP3510244B2 (de)
AT (2)	ATE447016T1 (de)
AU (1)	AU652997B2 (de)
CA (2)	CA2101774C (de)
DE (3)	DE971033T1 (de)
DK (2)	DK0568575T4 (de)
ES (2)	ES2335720T3 (de)
WO (1)	WO1992013069A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU652997B2 (en)	1991-01-21	1994-09-15	Elan Pharmaceuticals, Inc.	Test and model for alzheimer's disease
AU669493B2 (en) *	1991-11-12	1996-06-13	University Of Melbourne, The	A method for assaying and treating Alzheimer's disease
EP0644889A4 (de) *	1991-12-24	1996-01-10	Isis Pharmaceuticals Inc	ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION VON-g(b)-AMYLOID.
ES2204899T3 (es) *	1992-01-07	2004-05-01	Elan Pharmaceuticals, Inc.	Modelos de animales transgenicos para la enfermedad de alzheimer.
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
US5455169A (en)	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) *	1993-01-22	2001-12-11	Ludwig Institute For Cancer Research	MAGE-1 derived nona peptides, and compositions thereof
DK0730643T3 (da)	1993-10-27	2001-05-14	Elan Pharm Inc	Transgene dyr, som huser APP-allel med svensk mutation
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
CA2182311A1 (en)	1994-01-27	1995-08-03	Karen Hsiao	Transgenic non-human mammals with progressive neurologic disease
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0778886A4 (de) *	1994-09-01	2001-05-02		Transgenes tier welches eine familiäre form vom menschlichen amyloiden vorläuferprotein exprimiert
US6187992B1 (en)	1994-12-05	2001-02-13	Merck & Co., Inc.	Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) *	1994-12-06	1997-10-07	Rothenberg; Barry E.	Methods to identify hemochromatosis
AU6264996A (en) *	1995-06-07	1996-12-30	Athena Neurosciences, Inc.	Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
AUPN649395A0 (en) *	1995-11-10	1995-12-07	Ramsay Health Care Pty Ltd	A method for diagnosing alzheimer's disease
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
CA2183901A1 (en) *	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) *	1998-05-22	2005-08-23	Nanoproducts Corporation	Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (es) *	1997-06-04	2000-03-01	Euroespes S A	Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
FR2770217B1 (fr) *	1997-10-24	2001-12-07	Rhone Poulenc Rorer Sa	Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
JP2001521043A (ja) *	1997-10-24	2001-11-06	アバンテイス・フアルマ・エス・アー	プレセニリンとβ−アミロイドペプチドまたはその前駆体との相互作用を阻害し得るペプチド
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
KR20070013361A (ko) *	1998-09-24	2007-01-30	파마시아 앤드 업존 캄파니 엘엘씨	알츠하이머병 세크레타제
US6699671B1 (en) *	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
EP1165609A2 (de)	1999-02-10	2002-01-02	Elan Pharmaceuticals, Inc.	Menschliches beta-secretase enzym, inhibitoren und ihre zusammensetzungen und verwendungen
US6355425B1 (en) *	1999-03-26	2002-03-12	Billups-Rothenberg, Inc.	Mutations associated with iron disorders
US7056661B2 (en) *	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US6310048B1 (en)	1999-12-09	2001-10-30	St. Louis University	Antisense modulation of amyloid beta protein expression
CA2395926A1 (en) *	1999-12-28	2001-07-05	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1265849B1 (de) *	2000-03-23	2006-10-25	Elan Pharmaceuticals, Inc.	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
MXPA02012560A (es)	2000-06-30	2003-05-14	Elan Pharm Inc	Compuestos para tratar la enfermedad de alzheimer.
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
AU2001269127A1 (en) *	2000-07-06	2002-01-14	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	A novel app mutation associated with an unusual alzheimer's disease pathology
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
MXPA03011046A (es) *	2001-06-01	2004-06-25	Elan Pharm Inc	Hidroxialquilaminas.
AU2002315131A1 (en)	2001-06-13	2002-12-23	Elan Pharmaceuticals, Inc.	Aminediols as agents for the treatment of alzheimer's disease
WO2003002122A1 (en) *	2001-06-27	2003-01-09	Elan Pharmaceuticals, Inc.	Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
MXPA04000338A (es) *	2001-07-10	2004-07-23	Upjohn Co	Diamindioles para tratamiento de enfermedad de alzheimer.
US7053109B2 (en) *	2001-07-10	2006-05-30	Pharmacia & Upjohn Company	Aminediols for the treatment of Alzheimer's disease
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
US7244755B2 (en)	2001-10-04	2007-07-17	Pharmacia & Upjohn Company	Hydroxypropylamines
BR0214035A (pt) *	2001-11-08	2005-04-26	Elan Pharm Inc	Composto
AU2002352811A1 (en) *	2001-11-19	2003-06-10	Elan Pharmaceuticals, Inc.	Amino diols useful in the treatment of alzheimer's disease
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
WO2003072041A2 (en) *	2002-02-27	2003-09-04	Merck & Co., Inc.	Assays to monitor amyloid precursor protein processing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US7262208B2 (en) *	2002-04-30	2007-08-28	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of Alzheimer's disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
EP1565428A1 (de) *	2002-11-27	2005-08-24	Elan Pharmaceuticals, Inc.	Substituierte harnstoffe und carbamate
RU2390350C2 (ru)	2003-02-01	2010-05-27	Ньюралаб Лимитед	Активная иммунизация для создания антител к растворимому а-бета
PE20050420A1 (es) *	2003-04-21	2005-06-13	Elan Pharm Inc	Fenacilo 2-hidroxi-3-diaminoalcanos
MXPA05011150A (es) *	2003-04-21	2005-12-14	Elan Pharm Inc	2-hidroxi-3-diaminoalcanos de benzamida.
TWI374893B (en)	2003-05-30	2012-10-21	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US20050009110A1 (en) *	2003-07-08	2005-01-13	Xiao-Jia Chang	Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
US20060014790A1 (en) *	2004-01-21	2006-01-19	Varghese John	Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
US20050239832A1 (en) *	2004-03-09	2005-10-27	Varghese John	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528404A (ja)	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528402A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
CA2558034A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
WO2005110422A2 (en) *	2004-05-19	2005-11-24	Boehringer Ingelheim International Gmbh	Treatment of diseases associated with altered level of amyloid beta peptides
JP2008505929A (ja) *	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US7385085B2 (en) *	2004-07-09	2008-06-10	Elan Pharmaceuticals, Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CA2577392A1 (en) *	2004-08-27	2006-03-09	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
WO2006052691A2 (en) *	2004-11-05	2006-05-18	Wyeth	Pet and magnetic resonance for screening alzheimer's disease therapeutics
CA2590337C (en)	2004-12-15	2017-07-11	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
US20090124993A1 (en)	2005-02-17	2009-05-14	Burkly Linda C	Treating neurological disorders
JP4853892B2 (ja) *	2005-04-13	2012-01-11	独立行政法人国立精神・神経医療研究センター	変異対立遺伝子に対する特異的なＲＮＡｉの評価方法
JP5339901B2 (ja)	2005-05-10	2013-11-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	炎症傷害の処置および評価
GB0511861D0 (en) *	2005-06-13	2005-07-20	Merck Sharp & Dohme	Proteins
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
US20080293680A1 (en) *	2005-08-03	2008-11-27	Stefan Peters	Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
US20100168070A1 (en) *	2005-08-11	2010-07-01	Niklas Heine	Compounds for the treatment of alzheimer's disease
WO2007017509A1 (de) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Verbindungen zur behandlung der alzheimer erkrankung
EP1915339A1 (de) *	2005-08-11	2008-04-30	Boehringer Ingelheim International GmbH	Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
JP2009504614A (ja) *	2005-08-11	2009-02-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	アルツハイマー病の治療用化合物
CA2624904A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7932261B2 (en) *	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
WO2007092854A2 (en)	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092846A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2009017467A1 (en)	2007-07-27	2009-02-05	Elan Pharma International Limited	Treatment of amyloidogenic diseases
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
JP2009538924A (ja)	2006-06-01	2009-11-12	エランファーマシューティカルズ，インコーポレイテッド	Ａｐｐの神経活性断片
WO2008008360A1 (en)	2006-07-13	2008-01-17	Wyeth	Production of glycoproteins
EA016568B1 (ru)	2006-10-12	2012-05-30	Беллус Хелс (Интернэшнл) Лимитед	Способы, соединения, композиции и носители для доставки 3-амино-1-пропансульфоновой кислоты
ES2541546T3 (es)	2006-11-03	2015-07-21	Wyeth Llc	Sustancias que inhiben la glucólisis en cultivo celular
EP2115126B1 (de)	2007-03-02	2015-04-08	Wyeth LLC	Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8466118B2 (en) *	2007-04-23	2013-06-18	Saint Louis University	Modulation of blood brain barrier protein expression
CN101986785A (zh)	2007-05-11	2011-03-16	托马斯杰弗逊大学	治疗和预防神经退行性疾病和紊乱的方法
US8222264B2 (en)	2007-07-06	2012-07-17	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
NZ586831A (en) *	2008-01-28	2012-02-24	Janssen Pharmaceutica Nv	6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
US7786116B2 (en) *	2008-01-29	2010-08-31	Janssen Pharmaceutica N.V.	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2009105572A2 (en) *	2008-02-19	2009-08-27	Edunn Biotechonology Inc.	Antisense modulation of amyloid beta protein expression
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
JP6250394B2 (ja)	2010-08-19	2017-12-20	バック・インスティテュート・フォー・リサーチ・オン・エイジング	軽度の認知障害（ｍｃｉ）および関連障害の処置方法
AU2013235422B2 (en)	2012-03-19	2016-12-15	Buck Institute For Research On Aging	APP specific BACE inhibitors (ASBIs) and uses thereof
US9421245B2 (en)	2012-06-25	2016-08-23	The Brigham And Women's Hospital, Inc.	Targeted therapeutics
EP3653609B1 (de)	2013-02-12	2024-04-03	Buck Institute for Research on Aging	Hydantoine als modulatoren von bace-vermittelter app-verarbeitung
CA2918194C (en)	2013-03-27	2022-12-06	The General Hospital Corporation	Methods and agents for treating alzheimer's disease
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
EP3626832A3 (de)	2014-11-25	2020-05-13	The Brigham and Women's Hospital, Inc.	Verfahren zur identifizierung und behandlung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
WO2016085876A1 (en)	2014-11-25	2016-06-02	The Broad Institute Inc.	Clonal haematopoiesis
US11142505B2 (en)	2015-08-27	2021-10-12	The Regents Of The University Of California	Compositions for APP-selective BACE inhibition and uses therefor
US20190134000A1 (en)	2016-05-12	2019-05-09	Buck Institute For Research On Aging	Compounds to promote normal processing of app

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) *	1983-04-19	1985-01-08	The Wistar Institute Of Anatomy And Biology	HLA D Typing assay
JPS6147500A (ja) *	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja) *	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) *	1985-10-28	1987-05-09	Teijin Ltd	遺伝子断片およびプラスミド
DE3689123T2 (de) *	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3702789A1 (de) *	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
WO1989006689A1 (en) *	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) *	1988-03-22	1992-07-28	Cornell Research Foundation, Inc.	Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
WO1990013641A1 (en)	1989-05-10	1990-11-15	Sloan-Kettering Institute For Cancer Research	Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (de) *	1990-04-10	1991-10-16	Miles Inc.	Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
EP0527823A1 (de) *	1990-04-24	1993-02-24	The Regents Of The University Of California	Reinigung, nachweis und verfahren zur verwendung der protease-nexin-2
ES2217250T3 (es) *	1990-06-15	2004-11-01	Scios Inc.	Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992000521A1 (en) *	1990-06-29	1992-01-09	Case Western Reserve University	Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) *	1990-11-27	1992-02-25	Will L F & Cie Sa	Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
AU652997B2 (en) *	1991-01-21	1994-09-15	Elan Pharmaceuticals, Inc.	Test and model for alzheimer's disease
AU2765992A (en) *	1991-10-03	1993-05-03	Indiana University Foundation	Method for screening for alzheimer's disease
ES2204899T3 (es) *	1992-01-07	2004-05-01	Elan Pharmaceuticals, Inc.	Modelos de animales transgenicos para la enfermedad de alzheimer.
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en)	2005-04-27	2008-05-13	Samtec, Inc.	Elevated height electrical connector

1992
- 1992-01-21 AU AU11694/92A patent/AU652997B2/en not_active Expired
- 1992-01-21 DE DE0971033T patent/DE971033T1/de active Pending
- 1992-01-21 DE DE69233774T patent/DE69233774D1/de not_active Expired - Lifetime
- 1992-01-21 ES ES99109196T patent/ES2335720T3/es not_active Expired - Lifetime
- 1992-01-21 AT AT99109196T patent/ATE447016T1/de not_active IP Right Cessation
- 1992-01-21 DK DK92903304.1T patent/DK0568575T4/da active
- 1992-01-21 ES ES92903304T patent/ES2236682T5/es not_active Expired - Lifetime
- 1992-01-21 EP EP92903304A patent/EP0568575B2/de not_active Expired - Lifetime
- 1992-01-21 EP EP99109196A patent/EP0971033B1/de not_active Revoked
- 1992-01-21 DE DE69233468T patent/DE69233468T3/de not_active Expired - Lifetime
- 1992-01-21 JP JP50357592A patent/JP3510244B2/ja not_active Expired - Lifetime
- 1992-01-21 DK DK99109196T patent/DK0971033T3/da active
- 1992-01-21 WO PCT/GB1992/000123 patent/WO1992013069A1/en active IP Right Grant
- 1992-01-21 AT AT92903304T patent/ATE286971T1/de not_active IP Right Cessation
- 1992-01-21 US US08/104,165 patent/US5877015A/en not_active Expired - Lifetime
- 1992-01-21 CA CA2101774A patent/CA2101774C/en not_active Expired - Lifetime
- 1992-01-21 CA CA002372251A patent/CA2372251A1/en not_active Abandoned
1995
- 1995-06-05 US US08/464,250 patent/US6300540B1/en not_active Expired - Lifetime
2001
- 2001-12-27 JP JP2001397308A patent/JP3574432B2/ja not_active Expired - Lifetime
2003
- 2003-02-03 US US10/357,935 patent/US20030165958A1/en not_active Abandoned
2004
- 2004-04-30 JP JP2004136760A patent/JP2004261187A/ja active Pending

Also Published As

Publication number	Publication date
DK0568575T4 (da)	2010-12-20
CA2372251A1 (en)	1992-08-06
DK0568575T3 (da)	2005-05-23
EP0971033A3 (de)	2003-11-12
ES2335720T3 (es)	2010-03-31
EP0568575A1 (de)	1993-11-10
JP3574432B2 (ja)	2004-10-06
JP2004261187A (ja)	2004-09-24
US20030165958A1 (en)	2003-09-04
CA2101774C (en)	2011-01-04
ES2236682T5 (es)	2011-03-31
JPH06504441A (ja)	1994-05-26
EP0971033B1 (de)	2009-10-28
ES2236682T3 (es)	2005-07-16
US5877015A (en)	1999-03-02
DE69233774D1 (de)	2009-12-10
AU1169492A (en)	1992-08-27
JP3510244B2 (ja)	2004-03-22
DE69233468T2 (de)	2005-12-22
EP0568575B1 (de)	2005-01-12
DE69233468T3 (de)	2011-05-05
WO1992013069A1 (en)	1992-08-06
US6300540B1 (en)	2001-10-09
EP0568575B2 (de)	2010-11-03
DK0971033T3 (da)	2009-12-14
AU652997B2 (en)	1994-09-15
ATE447016T1 (de)	2009-11-15
CA2101774A1 (en)	1992-07-22
ATE286971T1 (de)	2005-01-15
EP0971033A2 (de)	2000-01-12
JP2002306195A (ja)	2002-10-22
DE971033T1 (de)	2001-05-03

Legal Events

Date	Code	Title	Description
2006-01-26	8363	Opposition against the patent
2011-01-13	8366	Restricted maintained after opposition proceedings

Publication	Publication Date	Title
DE69233468D1 (de)	2005-02-17	Prüfung und modell für alzheimers-krankheit
Bobek et al.	1992	Cystatins—inhibitors of cysteine proteinases
DE69839808D1 (de)	2008-09-11	Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
DK0868519T3 (da)	2006-05-08	Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
ES2170104T3 (es)	2002-08-01	Inhibidores de la produccion de proteinas de beta-amiloide.
NO931889L (no)	1993-11-29	Protease og beslektede DNA-forbindelser
ATE239797T1 (de)	2003-05-15	Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DK0528932T3 (da)	1996-07-01	Protein associeret med akut pancreatitis og midler til diagnose af akut pancreatitis
DK0948604T3 (da)	2004-11-22	Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE60133661D1 (de)	2008-05-29	Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
EP0716591A4 (de)	1998-02-04	Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
ATE417930T1 (de)	2009-01-15	Proteinkinase npk-110
ATE319819T1 (de)	2006-03-15	Humane hirn-spezifische carboxypeptidase b
MX9304839A (es)	1994-02-28	Marcador para determinar la inclusion de un bovino en un programa de cria.
ATE315582T1 (de)	2006-02-15	Verwendung von neuregulin-beta als indikator und/oder target
DK1129191T3 (da)	2006-07-17	Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme
ATE312914T1 (de)	2005-12-15	Rdgb-proteine
DK0592600T3 (da)	2000-04-17	Protein S polypeptider og anvendelse deraf
BR9813813A (pt)	2001-09-25	Sequência de dna, processo para proteger um paciente, peptìdio de sinal, anticorpo, imunoensaio, processo para diagnosticar uma prédisposição, processo para tratar um paciente humano, animal transgênico e linha de células
DE69519654T2 (de)	2001-05-17	htFIIIA Gen
DE69738945D1 (de)	2008-10-09	Rken
DE59009360D1 (de)	1995-08-10	Für das Plazentaprotein 9 (PP9) kodierende cDNA, ihre Isolierung und Verwendung.
DE3888078D1 (de)	1994-04-07	Veränderungsverfahren für Peptide und Proteine.